Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 14

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
,961 Accumulated deficit(418,779)(443,983)Accumulated other comprehensive loss(8,220)(36,090)Total stockholders’ equity1,257,667 1,175,966 Total liabilities and stockholders’ equity$1,367,787 $1,300,035  

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents

VERACYTE, INC.

 Condensed Consolidated Statements of Operations

 (Unaudited)

 (In thousands, except share and per share amounts)

 Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024Revenue:    Testing revenue$127,756 $109,536 $357,328 $306,809 Product revenue3,301 3,188 10,479 10,631 Biopharmaceutical and other revenue815 3,136 8,702 9,692 Total revenue131,872 115,860 376,509 327,132 Cost of revenue:Cost of testing revenue33,777 29,029 94,444 82,928 Cost of product revenue3,015 1,792 6,186 6,310 Cost of biopharmaceutical and other revenue1,091 3,112 7,361 9,762 Intangible asset amortization - cost of revenue2,707 2,917 7,959 8,741 Total cost of revenue40,590 36,850 115,950 107,741 Gross profit91,282 79,010 260,559 219,391 Operating expenses:Research and development15,981 17,574 49,965 50,004 Selling and marketing24,455 22,612 74,225 70,610 General and administrative27,278 25,742 93,417 83,697 Impairment of assets— 185 20,505 614 Intangible asset amortization - operating expenses622 880 1,865 2,499 Total operating expenses68,336 66,993 239,977 207,424 Income from operations22,946 12,017 20,582 11,967 Other income (loss), net(4,057)4,831 6,985